Nordea Investment Management AB Sells 17,304 Shares of Omnicell, Inc. $OMCL

Nordea Investment Management AB trimmed its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 13.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,267 shares of the company’s stock after selling 17,304 shares during the quarter. Nordea Investment Management AB owned about 0.25% of Omnicell worth $5,027,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in Omnicell during the second quarter worth approximately $26,000. First Horizon Corp acquired a new position in Omnicell in the third quarter valued at approximately $31,000. Farther Finance Advisors LLC lifted its stake in Omnicell by 784.8% in the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after buying an additional 1,036 shares during the period. LSV Asset Management bought a new position in shares of Omnicell during the 3rd quarter worth approximately $97,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Omnicell by 385.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after buying an additional 3,932 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Insider Transactions at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the sale, the executive vice president owned 96,717 shares in the company, valued at $3,355,112.73. This represents a 7.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.52% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on OMCL. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Wednesday, February 4th. Weiss Ratings lowered shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, March 2nd. Benchmark restated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Finally, Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $58.50.

Omnicell Stock Up 0.7%

OMCL stock opened at $35.20 on Friday. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.00. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The stock’s 50 day moving average is $41.00 and its 200-day moving average is $38.53. The firm has a market capitalization of $1.60 billion, a PE ratio of 880.22, a P/E/G ratio of 1.25 and a beta of 0.79.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). The company had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Sell-side analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.